Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation safeguards at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85% coverage when immunised 4 weeks before birth
• Antibodies from the mother transferred through placenta safeguard newborns from birth
• Protection possible with two-week gap before early delivery
• Vaccination in third trimester still offers meaningful infant protection

Strong evidence from current research

The performance of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month timeframe, providing robust and representative data of the vaccine’s practical effectiveness. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and prospective parents with trust in the vaccine’s proven efficacy across diverse populations and circumstances.

The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This stark contrast highlights the vaccine’s essential role in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Study design and parameters

The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology captured real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Grasping RSV and the risks

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests heaving as they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies recover with clinical support, a small but significant group succumb from RSV-related complications each year, making prevention through vaccination a essential public health priority for protecting the most vulnerable and youngest people in our communities.

• RSV produces lung inflammation, leading to severe breathing difficulties in infants
• Nearly 50% of newborns acquire the infection during their first few months alive
• Symptoms vary between mild colds to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK babies need serious hospital treatment for RSV annually
• Small numbers of babies die from RSV related complications annually in the UK

Adoption rates and professional guidance

Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.

The guidance from health authorities stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.

Regional variations in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences reflect differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data demonstrates robust and reliable protection regardless of geographical location.

• NHS trusts deploying varied communication campaigns to engage with women during pregnancy
• Regional disparities in vaccination coverage levels in different parts of England necessitate strategic intervention
• Regional health providers adapting programmes to meet local requirements and situations

Real-world impact and parent viewpoints

The vaccine’s outstanding effectiveness provides concrete gains for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this preventative solution, the 80% decrease in admissions equates to thousands of infants shielded from critical disease. Parents no longer face the distressing scenario of watching their newborns labour to breathe or labour to feed, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal lung health, providing expectant mothers a proactive tool to safeguard their youngest infants during those crucial first weeks.

For families like that of Malachi, whose severe RSV infection resulted in profound brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab emphasises the transformative consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to pregnant women in their third trimester, converting what was once an inevitable seasonal threat into a manageable health risk.